Related Press Release
Altasciences has completed a Phase I study for the development of gimsilumab, a fully human monoclonal antibody that targets granulocyte-macrophage colony stimulating factor (GM-CSF), found to be up-regulated in SARS CoV-2 in patients with or at risk of developing acute respiratory distress syndrome (ARDS).
Webinar - Cracking the pill: A journey of exploring abuse deterrent methods from the laboratory, clinic, and to the real user
The evolving laboratory and clinical methods, as they apply to both opioids and stimulants. Included is a rare candid interview with recreational drug users that will provide you with a direct, unique perspective around their behaviors and experiences with existing abuse-deterrent formulations.
A discussion on how bioanalytical data is used in early phase clinical trials to advance drug development.